Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine if estrogen receptor-targeted therapy
with fulvestrant used in combination with Everolimus is an effective and safe therapy for
women with hormone receptor positive metastatic breast cancer after failure of aromatase
inhibitor therapy.